Category: Regulatory

As of March 19, 2025, compounded tirzepatide is no longer broadly available, following the FDA's determination that the national shortage of the branded medication had resolved. This major regulatory shift requires patients to know how to get tirzepatide after March 2025 through approved channels for safety and efficacy.

In December 2024, the U.S. Food and Drug Administration (FDA) officially declared the tirzepatide drug shortage resolved, significantly altering how patients can access this medication. For those previously relying on compounded versions, this regulatory shift raises a critical question: **Am I still going to be able to get tirzepatide?**.